Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin Rapid Communication  by Bahlmann, Ferdinand H. et al.
Kidney International, Vol. 64 (2003), pp. 1648–1652
Endothelial progenitor cell proliferation and differentiation is
regulated by erythropoietin
Rapid Communication
FERDINAND H. BAHLMANN,1 KIRSTEN DEGROOT,1 THORSTEN DUCKERT, EVA NIEMCZYK,
ELISABETH BAHLMANN, SASCHA M. BOEHM, HERMANN HALLER, and DANILO FLISER
Division of Nephrology, Department of Internal Medicine, Hanover Medical School, Hanover, Germany; and Phenos GmbH,
Hanover, Germany
Endothelial progenitor cell proliferation and differentiation is
regulated by erythropoietin.
Background. Circulating bone marrow–derived endothelial
progenitor cells (EPCs) promote vascular reparative processes.
In humans, their number correlate with endothelial function
and cardiovascular risk. We tested the hypothesis that darbe-
poetin alfa [i.e., a recombinant analogue of the cytokine eryth-
ropoietin (EPO)] stimulates proliferation and differentiation
of EPCs.
Methods. We assessed CD34 circulating stem cells (cSCs)
in whole blood using flow cytometry and, in addition, prolifera-
tion/differentiation of EPCs in an in-vitro assay during 6 weeks
of a standard darbepoetin therapy in eight patients with renal
anemia.
Results. Darbepoetin treatment caused a significant increase
in the number of CD34 cSCs (week 2, 193%  46%; and
week 6, 298%  90%; P  0.05 vs. baseline). In addition,
darbepoetin markedly increased the number of functionally
active EPCs (week 2, 256%  48%; and week 6, 299%  59%;
both P  0.01 vs. baseline). The effect of darbepoetin on func-
tional activity of EPCs assessed in a tube formation assay
was dose dependent. Administration of darbepoietin caused
activation of protein kinase B (Akt) in cultured EPCs.
Conclusion. A standard treatment with darbepoetin mark-
edly enhances EPC proliferation and differentiation in renal
patients. The use of recombinant EPO analogues may be a
novel and safe therapeutic approach in patients with vascular
pathology.
Bone marrow–derived endothelial progenitor cells
(EPCs) originate from CD34 stem cells. The latter dif-
ferentiate via separate pathways also into erythrocytes,
thrombocytes, various lineages of leukocytes, and into
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endothelial cells [1, 2]. Circulating EPCs promote vascu-
lar reparative processes, and increased neovasculariza-
tion by these cells improved cardiac function after experi-
mental myocardial ischemia [3–10]. In patients with
myocardial infarction, the outcome is strongly correlated
to the number of mobilized EPCs [11]. Even in appar-
ently healthy subjects, their numbers significantly corre-
late with endothelial function and cardiovascular risk
[12]. Thus, stimulation of EPC number and/or function
might be a new therapeutic approach in cardiovascular
medicine.
The cytokine erythropoietin (EPO) stimulates eryth-
rocyte differentiation, and its (recombinant) analogues
are currently used for treatment of anemia in renal pa-
tients and in patients with malignant diseases. EPO has
also direct biologic effects on endothelial cells, and the
vasculature seems to be an important EPO target [13–15].
Thus, EPO could affect EPC proliferation and differenti-
ation as well. We tested the hypothesis that the recombi-
nant EPO analogue darbepoetin modulates the number
of functionally active EPCs. For this purpose, we assessed
CD34 circulating hematopoietic stem cells (cSCs) in
whole blood using flow cytometry, and proliferation/dif-
ferentiation behavior of EPCs in an in-vitro assay during
a standard course of darbepoetin therapy in eight pa-
tients with renal anemia.
METHODS
The study protocol was approved by the Hannover
Medical School Ethics Committee. Informed consent was
obtained from eight patients with stable advanced renal
failure (five males, three females, age 65 4 years, serum
creatinine 339  102 mol/L, hematocrit 27.7  1.2%).
None of the patients had received blood transfusions for
at least 3 months before study entry, and patients with
concomitant malignant diseases, bleeding conditions, re-
cent cardiovascular events, or active inflammation were
excluded from the study. Four patients had stable coro-
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nary artery disease and three had peripheral occlusive
disease. All patients received darbepoetin alfa for treat-
ment of renal anemia (Aranesp) (Amgen, Thousand
Oaks, CA, USA). The starting weekly dose of darbepoe-
tin was 20  3 g. Three patients received statin therapy
for at least 6 months. The dose of all medications was
kept constant 4 weeks before and during the study pe-
riod. We took blood samples for blood counts and study
purposes during regular outpatient visits before and after
2 and 6 weeks of treatment. Blood concentrations of
vascular endothelial growth factor (VEGF) and basic
fibroblast growth factor (bFGF) were measured before
and during darbepoetin therapy using enzyme-linked im-
munosorbent assay (ELISA) (R&D Systems, Minneapo-
lis, MN, USA).
We assessed the total number of cSCs before and
during darbepoetin therapy using a gating strategy for
flow cytometry on the basis of the International Society
of Hematotherapy and Graft Engineering (ISHAGE)
guidelines [16]. The CD34 and CD45 expression patterns
as well as the morphologic qualities of cSCs were used
for their detection. For this purpose, we incubated 100L
of patients whole ethylenediaminetetraacetic acid (EDTA)
blood with fluorescein isothiocyanate (FITC)-labeled
monoclonal mouse anti-human-CD45 antibody (Coulter
Beckman, Krefeld, Germany) and phycoerythrin (PE)-
labeled monoclonal mouse anti-human-CD34 antibody
(Coulter Beckman). In addition, we added a PE-labeled
mouse IgG1-antibody (Coulter Beckman) to a second
anti-CD45–stained blood sample as the isotype control.
Subsequent lysis was done with ammonium chloride. We
acquired at least 200,000 CD45 cells using an Epics XL
cytometer (Coulter Beckman), and the number of cSC
was expressed per microliter using calibration beads
(Coulter Beckman). Their number was assessed by a
blinded investigator.
For cultivation of EPCs, we isolated peripheral blood
mononuclear cells from patients blood using density gra-
dient centrifugation with Bicoll (Biochrome, Berlin, Ger-
many), and seeded 107 cells on 6-well plates coated with
human fibronectin (Sigma Chemical Co., St. Louis, MO,
USA) in endothelial basal medium (EBM-2) (Clonetics,
Walkersville, MD, USA). The medium was supple-
mented with EGM-2 Single Quots containing fetal bo-
vine serum (FBS), human VEGF-A, human fibroblast
growth factor-B (FGF-B), human epidermal growth fac-
tor (EGF), insulin-like growth factor-1 (IGF-1), and
ascorbic acid in appropriate amounts. After 4 days, non-
adherent cells were removed, and 106 of the adherent
cells were reseeded on fibronectin-coated plates in order
to normalize cell number and to obtain a homogenous
cell population of adherent EPCs. After 7 days in culture,
we determined the type of the attached blood mono-
nuclear cells with fluorescent chemical detection using
1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine-
labeled acetylated low-density lipoprotein (acLDL-DiI,
Molecular Probes, Eugene, OR, USA) and FITC-labeled
Ulex europaeus agglutinin-1 (UEA-1) (Sigma Chemical
Co.). A blinded investigator viewed at least four randomly
selected high-power fields with an inverted fluorescent
microscope (Leica, Wetzlar, Germany) and counted
double-stained cells (UEA-1 and acLDL-DiI) as EPCs
[17–19].
In order to study the functional activity of EPCs, we
used a tube formation assay as described previously [17].
Briefly, acLDL-DiI–labeled EPCs obtained from healthy
volunteers were co-plated with human umbilical vein-
endothelial cells (HUVECs) on a 4-well glass slide pre-
coated with 250 L of ECMatrixTM (Chemicon Interna-
tional, Hofheim, Germany) in 500 L EBM-2 with
addition of 0, 0.001, 0.0025, or 0.005 g/mL of darbepoe-
tin (equivalent to weekly therapeutic doses of 0, 5, 15,
and 30 g). After 4 hours of incubation in 5% CO2
humidified atmosphere at 37C, the three-dimensional
organization of the cells was examined under an inverted
phase-contrast photomicroscope using following grades:
0, individual cells, well separated; 1, cells begin to migrate
and align themselves; 2, capillary tubes visible, no sprout-
ing; 3, sprouting of new capillary tubes visible; 4, closed
polygons begin to form; and 5, complex mesh-like struc-
tures develop. A blinded investigator examined 10 ran-
domly selected high-power fields. In addition, the influ-
ence of darbepoetin on intracellular protein kinase B
(Akt) activation was assessed in vitro in cultured day
7 EPCs from healthy volunteers. Polyclonal antibodies
against Phospho-Akt (Ser473) and Total-Akt (both Cell
Signaling Technology, Inc., Beverly, MA, USA) were
used to assess Akt activation by Western immunoblot-
ting protocol as described in detail elsewere [20].
Statistical analysis of data on patients’ whole-blood
CD34 cSCs and the number of EPCs in culture during
6 weeks of darbepoetin treatment was done using a non-
parametric comparison of repeated observations (i.e., a
Kruskal-Wallis test) (InStat software, GraphPad Soft-
ware, Inc., San Diego, CA, USA). The same test was
used in order to compare data of the tube formation
assay. The statistical significance was set at a P level
of 0.05. Data are expressed as mean  SEM.
RESULTS
The absolute number of cSCs per microliter whole
blood in patients before treatment was 2.3 0.9L. This
number was set as baseline (100%). For comparison,
the absolute number of cSCs in eight healthy age- and
gender-matched subjects (age 66  5 years, hematocrit
43.4  1.2%) was 3.0  0.9 L. In patients, we observed
a significant increase (P 0.05) of cSCs during darbepoe-
tin treatment to 193%  46% at week 2 and 298% 
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Fig. 1. The number of circulating stem cells (cSCs) in whole blood of
eight renal patients before and during darbepoetin treatment. #P 
0.05 comparison between baseline and week 6.
90% at week 6 (Fig. 1). The total number of EPCs in
cell culture before treatment in patients was 169 24 per
high power field. This number was set as baseline (100%)
as well (Fig. 2). The absolute number of EPCs in healthy
subjects was 309  45 per high power field. At 2 weeks
of darbepoetin treatment, the EPC number in patients
significantly increased to 256%  48%, and increased
further to 299%  56% at week 6 (both P  0.01 vs.
baseline). We found a marked increase in EPC number in
every treated individual. Figure 3 shows a representative
photomicrograph of cultured EPCs in one patient before
and 6 weeks after the initiation of darbepoetin therapy.
Figure 4 presents the results of the tube formation assay.
Addition of escalating darbepoetin doses to the media
significantly enhanced the formation of tube-like struc-
tures to which EPCs made a substantial contribution.
Furthermore, application of darbepoetin to EPCs in cell
culture caused a marked and time-dependent phosphor-
ylation of Akt in EPCs (Fig. 5).
In accordance with the European Renal Association
Guidelines on the treatment of renal anemia [21], we
achieved a mean target hematocrit level of 35.9% 1.8%
after 6 weeks of darbepoetin therapy (from 27.7% 
1.2%). There were no significant changes in VEGF blood
levels in patients before (209  68 pg/mL), after 2 weeks
(154  25 pg/mL), and at the end of darbepoetin treat-
ment (169  55 pg/mL). Blood concentrations of bFGF
in patients were not detectable before and during treat-
ment with darbepoetin.
DISCUSSION
The striking finding of the present study was that treat-
ment with darbepoetin significantly affects the number
of cSCs and promotes the proliferation and differentia-
tion of EPCs in renal patients. Importantly, this effect
Fig. 2. Quantitative assessment of cultured endothelial progenitor cells
(EPCs) from eight renal patients during darbepoetin therapy. Admin-
istration of darbepoetin clearly resulted in a marked increase in total
EPC number within 6 weeks of therapy. #P  0.01 comparison of
week 2 and week 6 vs. baseline.
was achieved with a standard therapeutic dose, and it was
by far more marked (i.e., about 300%). than the increase
in total erythrocyte number (i.e., about 30%). These ob-
servations together with the increased viability of EPCs
in the tube formation assay permit the conclusion that
the EPO analogue darbepoetin is a potent regulator of EPC
proliferation and differentiation. Furthermore, VEGF and
bFGF blood levels in our patients did not change during
treatment, pointing to a direct effect of darbepoetin on
EPCs. Our results are in line with findings that the cyto-
kine EPO is a major regulator of vascular formation and
organ growth in the embryo [22]. Embryonic vasculogen-
esis starts as a cluster formation of hemangioblasts, and
the cells at the periphery of these clusters differentiate
into EPCs, whereas the central ones differentiate into
hematopoietic stem cells [23]. We thus hypothesize that
EPO remains a key molecule in the process of vascular
repair and (neo-) angiogenesis by stimulating EPCs in
adults as well. In accordance with data from experiments
using statins, we have shown that darbepoetin also acti-
vates the intracellular Akt pathway in EPCs [24–26].
Patients with renal failure are at high risk for cardio-
vascular events, and most die of complications related
to atherosclerosis [27]. Possibly, impaired vascular repair
mechanisms may contribute to the problem. Treatment
with recombinant human EPO reduces left ventricular
mass, ameliorates exercise related cardiac ischemia, and
improves outcome in patients with advanced renal failure
[28]. These salutary actions are thought to be the conse-
quence of improved tissue oxygenation, but our results
suggest a complementary explanation. A reduced num-
ber and/or impaired function of EPCs due to EPO defi-
ciency could be causal factor for the high cardiovascular
morbidity and mortality in renal patients, and replace-
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Fig. 3. Representative photomicrograph of cultured endothelial pro-
genitor cells (EPCs) from a patient with renal anemia before and after
6 weeks of darbepoietin therapy. EPCs were stained with both Ulex
europaeus agglutinin-1 (UEA-1) fluorescein isothiocyanate (FITC) (green
fluorescence) and 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine-
labeled acetylated low-density lipoprotein (acLDL-DiI) (red fluorescence).
ment therapy with recombinant EPO analogues would
ameliorate this problem via the endothelial cell pathway.
In line with this assumption are results of a prospective
controlled study in patients with heart failure, in whom
treatment with recombinant EPO improved outcome
[29]. Moreover, findings of a recently published study
suggest that EPO blood levels are a major determinant of
EPC number in patients with acute myocardial syndrome
[30]. Thus, administration of EPO analogues could be
beneficial in other cardiovascular high-risk populations
as well. The results of a recent experimental study are of
considerable interest in this respect. EPO reduced the
extent of stroke in laboratory animals [31]. Further stud-
Fig. 4. Dose-dependent effect of darbepoetin alfa on endothelial pro-
genitor cells (EPCs). (A ) Phase contrast images demonstrating the
effect of darbepoetin on formation of tube-like structures by co-cultured
EPCs in an in vitro angiogenesis assay. (B ) Representative photomicro-
graphs of tube formation with 0.005 g/mL darbepoetin. Fluorescent-
labeled EPCs (red) were co-plated with human umbilical vein endothe-
lial cells (HUVECs) (transparent) to form tubular structures. Both
cell types were stained with endothelial cell-specific Ulex europaeus
agglutinin-1 (UEA-1) (green fluorescence). Superimposed phase-con-
trast and fluorescent images of identical fields reveal that EPCs made
a substantial contribution to the tubular network. (C ) Quantitative
assessment of the tube formation index. #P  0.05 vs. 0 g/mL.
Fig. 5. Representative Western immunoblots of Akt phosphorylation
are shown as time-dependent changes in Akt phosphorylation at serine
473 after exposure of endothelial progenitor cells (EPCs) to darbepoie-
tin (0.005 g/mL). p-Akt, phospho Akt (active protein kinase B); Akt 1,
total Akt (active and inactive protein kinase B).
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ies evaluating the role of EPO in EPC-mediated vascular
repair are therefore warranted.
CONCLUSION
Our results document that the EPO analogue darbe-
poetin stimulates endothelial progenitor cell prolifera-
tion and differentiation. Therapy with recombinant EPO
or EPO analogues could therefore constitute a new prom-
ising therapeutic strategy in patients with cardiovascular
diseases [32].
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